Aurinia Pharmaceuticals Inc.
A biopharmaceutical company in Victoria, British Columbia, that develops and sells treatments for autoimmune diseases. Its signature drug, LUPKYNIS (voclosporin), is an oral medicine for adults with lupus nephritis, a kidney inflammation caused by lupus. The company began in 1993 in Edmonton as Isotechnika Pharma, then took the Aurinia name in 2013 when it acquired Aurinia Pharma Corp. and refocused on voclosporin; the drug won US approval in 2021. The brand name Lupkynis blends "lupus" with a distinctive suffix, and "Aurinia" also names a golden-flowered garden plant called basket of gold.
Bought 814.6K
Bought 5.00M
Granted 1.65M · Sold 487.5K
Granted 547.3K · Sold 165.6K
Granted 603.9K · Sold 180.2K
Granted 498.6K · Sold 152.8K
Granted 195.5K · Sold 51.9K
Sold 30.1K
Granted 103.2K · Sold 40.5K
Granted 116.1K
Granted 116.1K
Granted 12.1K · Sold 4.9K
Sold 5.3K
Granted 12.1K · Sold 5.6K
Granted 30.0K · Sold 5.2K
Granted 30.0K · Sold 4.6K
Sold 5.6K
Sold 520
Granted 20.6K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Tang Capital Management LLC +1 co-filer10% owner, Chief Executive Officer, Director, 10% owner · 5 transactions | — | 13.04M | — | 814.6K | — |
| Tang KevinDirector · 18 transactions | — | 12.23M | — | 5.00M | — |
| Greenleaf PeterChief Executive Officer, Director · 11 transactions | +87.3% | 1.84M | 1.65M | — | 487.5K |
| Donley Matthew MaxwellChief Operating Officer · 11 transactions | +68.7% | 680.3K | 547.3K | — | 165.6K |
| Robertson Stephen P.Chief Legal Officer · 12 transactions | +105% | 621.4K | 603.9K | — | 180.2K |
| Miller Joseph MChief Financial Officer · 11 transactions | +74.1% | 576.4K | 498.6K | — | 152.8K |
| Habig Scott MichaelChief Commercial Officer · 4 transactions | +45.9% | 456.3Kas of Aug 2024 | 195.5K | — | 51.9K |
| Knappertz VolkerEVP, Research and Development · 2 transactions | -7.3% | 319.1Kas of Feb 2024 | — | — | 30.1K |
| Keenan GregSVP, Chief Medical Officer · 7 transactions | — | 154.4K | 103.2K | — | 40.5K |
| Cole RyanChief Operating Officer · 1 transaction | — | 116.1K | 116.1K | — | — |
| Hearne Michael SChief Financial Officer · 1 transaction | — | 116.1K | 116.1K | — | — |
| Jayne David R.W.Director · 2 transactions | +14.6% | 56.5Kas of Nov 2024 | 12.1K | — | 4.9K |
| Billen DanielDirector · 1 transaction | -15.7% | 28.1Kas of May 2024 | — | — | 5.3K |
| Leversage JillDirector · 2 transactions | +35.2% | 25.1Kas of Nov 2024 | 12.1K | — | 5.6K |
| Smith Karen L.Director · 3 transactions | — | 24.8Kas of Nov 2024 | 30.0K | — | 5.2K |
| Bailey Jeffrey AllenDirector · 4 transactions | — | 22.8K | 30.0K | — | 4.6K |
| MacKay-Dunn R. HectorDirector · 1 transaction | -23.2% | 18.6Kas of May 2024 | — | — | 5.6K |
| Balakrishnan BrindaDirector · 1 transaction | -2.9% | 17.5Kas of May 2024 | — | — | 520 |
| Johnson Craig ADirector · 2 transactions | — | 14.6K | 20.6K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: +4.67M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.